资本市场融合
Search documents
陕西企业赴港上市对接会在香港举行
Shan Xi Ri Bao· 2026-02-05 00:50
"公司是行业内唯一同时获得中国船级社(CCS)四类认可证书的企业,处于国内海洋科技领域第 一梯队。"陕西欧卡电子智能科技有限公司联合创始人池雨豪说,香港是全球航运、金融与科技资本的 重要交汇点。公司计划将香港作为全球业务与出海中心,重点对接海外特别是欧洲市场。(记者:苏 怡) 近年来,陕西企业国际化步伐持续加快,对跨境金融、专业服务及国际市场资源的需求日益增加。 香港在金融、法律、咨询及国际网络方面的专业优势,与陕西产业发展需求形成高度互补。作为"服务 陕西企业赴港上市及企业出海行动计划"的落地举措之一,本次对接会着力推动陕西企业在港实现"上市 —融资—发展"全流程衔接,不仅为陕西企业搭建了走向国际资本市场的"快车道",还为香港服务机构 拓展内地市场、参与西部发展提供了重要平台。随着"服务陕西企业赴港上市及企业出海行动计划"深入 推进,陕港两地将进一步在产业投资、科技合作、绿色金融及专业服务等领域探索新模式、拓展新空 间。 近日,由香港贸易发展局、陕西省委金融办、陕西省贸促会及中信集团联合主办的陕西企业赴港上 市对接会在香港举行。陕港两地70多位政府代表、金融机构高管及企业负责人参加此次对接会,标志着 陕港合 ...
恒生创新药指数成分股调整今日生效,CXO企业被剔除
Zhong Zheng Wang· 2025-08-11 05:01
Group 1 - The Hang Seng Innovation Drug Index and the Hang Seng Hong Kong Stock Connect Innovation Drug Index have undergone a composition adjustment effective from August 11 [1] - The new calculation method excludes companies primarily engaged in the CXO industry, including Contract Research Organizations (CRO), Contract Manufacturing Organizations (CMO), and Contract Development and Manufacturing Organizations (CDMO) [1] - The adjustment introduces a requirement for Southbound trading connectivity, meaning only stocks that meet the Hong Kong Stock Connect criteria can be included, enhancing investment convenience [1] Group 2 - The Hang Seng Innovation Drug Index will maintain a fixed number of 40 constituent stocks, with eligible securities selected based on their relevance to innovative drug business [1] - The adjustment reflects the latest development trends in the Hong Kong innovative drug sector, providing investors with a more precise market benchmark [1] - The changes also indicate a trend of deeper integration between the capital markets of the two regions as the connectivity mechanism continues to improve [1]